B7x (B7-H4 or B7S1) is the seventh member of the B7 family, and its in vivo function remains largely unknown. Despite new genetic data linking the B7x gene with autoimmune diseases, how exactly it contributes to peripheral tolerance and autoimmunity is unclear. In this study, we showed that B7x protein was not detected on APCs or T cells in both human and mice, which is unique in the B7 family. Because B7x protein is expressed in some peripheral cells such as pancreatic b cells, we used a CD8 T cell-mediated diabetes model (AI4ab) in which CD8 T cells recognize an endogenous self-Ag, and found that mice lacking B7x developed more severe diabetes than control AI4ab mice. Conversely, mice overexpressing B7x in the b cells (Rip-B7xAI4ab) were diabetes free. Furthermore, adoptive transfer of effector AI4ab CD8 T cells induced diabetes in control mice, but not in Rip-B7xAI4ab mice. Mechanistic studies revealed that pathogenic effector CD8 T cells were capable of migrating to the pancreas but failed to robustly destroy tissue when encountering local B7x in Rip-B7xAI4ab mice. Although AI4ab CD8 T cells in Rip-B7xAI4ab and AI4ab mice showed similar cytotoxic function, cell death, and global gene expression profiles, these cells had greater proliferation in AI4ab mice than in RIP-B7xAI4ab mice. These results suggest that B7x in nonlymphoid organs prevents peripheral autoimmunity partially through inhibiting proliferation of tissue-specific CD8 T cells, and that local overexpression of B7x on pancreatic b cells is sufficient to abolish CD8 T cell-induced diabetes. The Journal of Immunology, 2012, 189: 4165-4174. T he interaction between the B7 family and their receptor CD28 family generates positive costimulation and negative coinhibition, which are necessary for the regulation of peripheral T cell activation and tolerance. B7x (B7-H4 or B7S1) is the seventh member of the B7 family and is able to inhibit in vitro T cell proliferation and cytokine production in the presence of TCR signaling (1-3). In contrast with classical B7-1 and B7-2, whose expression is generally limited to professional APCs in lymphoid organs, B7x mRNA is detected more highly in nonlymphoid organs than lymphoid organs (1, 4). The combination of the in vivo mRNA expression pattern and the in vitro T cell coinhibitory capability of B7x suggests that the B7x pathway may be important in regulating tolerance and autoimmunity in nonlymphoid organs.
T he interaction between the B7 family and their receptor CD28 family generates positive costimulation and negative coinhibition, which are necessary for the regulation of peripheral T cell activation and tolerance. B7x (B7-H4 or B7S1) is the seventh member of the B7 family and is able to inhibit in vitro T cell proliferation and cytokine production in the presence of TCR signaling (1) (2) (3) . In contrast with classical B7-1 and B7-2, whose expression is generally limited to professional APCs in lymphoid organs, B7x mRNA is detected more highly in nonlymphoid organs than lymphoid organs (1, 4) . The combination of the in vivo mRNA expression pattern and the in vitro T cell coinhibitory capability of B7x suggests that the B7x pathway may be important in regulating tolerance and autoimmunity in nonlymphoid organs.
Most autoimmune diseases are genetically complex, and variation at a large number of genes influences disease susceptibility and progression (5, 6) . Type 1 diabetes (T1D), an autoimmune disease, is characterized by self-reactive T cells that recognize and destroy the insulin-producing b cells of the pancreas, resulting in a breakdown of glucose homeostasis. Genetic mapping and genephenotype studies in mice and humans have revealed that, in addition to the MHC locus, .20 insulin-dependent diabetes loci contribute to T1D development (7) . One of these loci, the insulindependent diabetes 10 locus on mouse chromosome 3, contains the B7x gene (8) , suggesting a potential role of B7x in T1D. Murine studies support this notion because B7x suppresses CD4 T cell-mediated T1D (4) . Juvenile idiopathic arthritis, another autoimmune disease, is the most common chronic rheumatic disease of childhood, and the majority of genetic risk factors remain to be elucidated. Recently, a genome-wide association analysis identified 10 single-nucleotide polymorphisms in noncoding regions of the B7x gene that are strongly associated with juvenile idiopathic arthritis (9) . In addition, two single-nucleotide polymorphisms in the B7x gene are significantly associated with increased serum IgE in children (10) . Despite these recently discovered genetic data linking the B7x gene to different autoimmune diseases, it is unclear how B7x contributes to peripheral tolerance and autoimmunity.
In this study, we found that endogenous B7x protein was not detected on APCs and T cells of either human or mouse. Because B7x protein is expressed on pancreatic b cells (4), we crossed B7x-deficient mice (B7x (AI4ab) specific for an Ag expressed by pancreatic b cells (11, 12) to study the role of tissue-expressed B7x in CD8 T cellmediated organ-specific autoimmune destruction. B7x 2/2 mice developed exacerbated diabetes induced by b cell Ag-specific AI4ab CD8 T cells, whereas overexpression of B7x on pancreatic b cells was sufficient to completely abrogate diabetes induced by the same Ag-specific CD8 T cells. In addition, Rip-B7x transgenic mice were resistant to diabetes induced by adoptive transfer of effector AI4ab CD8 T cells. The absence of diabetes in Rip-B7x transgenic mice was not due to a primary defect in cytotoxic function of pathogenic CD8 T cells, but rather was most likely due to the inhibitory effect of tissue-expressed B7x on proliferation of pathogenic CD8 T cells. , and AI4b/B6.H2 g7/g7 mice were previously described (4, 13 . All mice were maintained under specific pathogenfree conditions at the Albert Einstein College of Medicine following protocols approved by the Institutional Animal Care and Use Committee.
Materials and Methods

Mice
Abs and tetramer for flow cytometry
Cells were preincubated with anti-CD16/CD32 and then stained with Abs against B7x (clones 9 and H74, [eBioscience]; BAF2154 [R&D Systems]; our own clone 19D6, 15D12, 12D11, and 1H3 [4] ) or other markers (eBioscience, BD Pharmingen, AbD Serotec). For intracellular staining, cells were fixed, permeabilized, and then stained. Alexa 647-conjugated MimA2 (YAIENYLEL)/H-2D b tetramer was made by the National Institutes of Health Tetramer Core Facility. Alive and dead cells were detected using LIVE/DEAD marker (Invitrogen). Samples were examined using a FACSCalibur or LSRII (BD Biosciences) with subsequent analysis of data in FlowJo (Tree Star).
Stimulation of immune cells
Human PBMCs were isolated by Ficoll-Hypaque gradient centrifugation, and T cells were stimulated with PHA (5 mg/ml) for 72 h or PMA (50 ng/ ml) and ionomycin (1 mg/ml) for 48 h. B cells were purified from PBMC with CD19 MicroBeads (Miltenyi Biotec) and activated with LPS (60 mg/ ml) for 72 h or PMA/ionomycin for 36 h. Monocytes were purified from PBMC with CD14 MicroBeads and activated with LPS (100 ng/ml) and IFN-g (100 ng/ml) for 36 h. Monocyte-derived dendritic cells (DCs) and CD34-derived Langerhans cells (LCs) were generated and activated with CD40L (soluble rhuCD40-L trimer, 0.5 mg/ml; Immunex), LPS (60 mg/ ml), PMA (50ng/ml)/ionomycin (1 mg/ml), or cytokine mixture (2 ng/ml IL-1b, 1000 IU/ml IL-6, 10 ng/ml TNF-a, and 5 mM/ml PGE 2 ) as described previously (14) . Mouse T cells were stimulated with Con A (0.02-20 mg/ml) or plate-coated anti-CD3/CD28 (0.1-40 mg/ml) for 72 h, or PMA/ionomycin for 48 h. Th1 and Th2 cell lines were generated from OT-II mice as described previously (15) . B cells were activated with LPS (2.5-80 mg/ml) or anti-IgM F(ab9) 2 fragment (2.5-80 mg/ml) for 72 h, or PMA/ ionomycin for 48 h. Nematode Brugia malayi infection-induced alternatively activated macrophages and DCs were obtained as described previously (16) . Infiltrating immune cells in the lung from 4T1-induced lung metastasis or Streptococcus pneumoniae-induced lung (17) infection were also used.
Assessment of diabetes development
Diastix (Bayer) testing strips were used to determine urine glucose levels in mice. Mice were considered to be diabetic after two consecutive measurements exceeding 250 mg/dl.
Histology and immunohistochemistry
Mouse organs were fixed with 4% paraformaldehyde and embedded in paraffin. Sections were stained with H&E or Gomeri aldehyde-fuchsin (GAF) for pancreatic b cells by the Histotechnology and Comparative Pathology Core Facility. For immunohistochemical staining, tissues were collected from mice and fixed in 10% neutral-buffered formalin (Fisher) before paraffin embedding. After clearing in xylene washes and rehydration, Ag retrieval was performed in a vegetable steamer in Tris/EDTA Ag retrieval solution. Sections were biotin blocked using the ScyTek Biotin Blocking kit; then normal blocking was done using horse serum (Vector Labs). Sections were incubated with a biotinylated anti-B7-H4 Ab or isotype IgG control (R&D Systems) overnight at 4˚C and then blocked for endogenous peroxidase for 10 min in 1% H 2 O 2 . Sections were incubated in ABC reagent (Vector Labs) for 20 min; then the tyramide amplification kit (Invitrogen) was used, followed again with the ABC reagent for 20 min. Sections were developed with the DAB kit (Vector Labs), counterstained with hematoxylin, dehydrated, cleared in xylene, and mounted.
Adoptive transfer of AI4ab CD8 T cells A total of 2 3 10 7 splenocytes from AI4ab/B6 g7/g7 mice were injected i.v. into sublethally irradiated mice (750 rad) as described previously (18), and recipients were monitored for diabetes. Alternatively, splenocytes from AI4ab/B6 g7/g7 mice were stimulated with MimA2 peptide (3.5 mg/ml), irradiated C57BL/6.H2 g7/g7 splenocytes (2000 rad), LPS (0.18 mg/ml), and IL-2 (10 U/ml) for 5 d. The activated AI4ab CD8 T cells were then transferred i.v. into mice at 5 3 10 6 per mouse, and recipients were monitored for diabetes.
Cell-mediated cytotoxicity assay CD8 T cells (.95% AI4ab cells) from AI4ab and Rip-B7xAI4ab mice were purified with Miltenyi beads and then incubated with MimA2 peptide-pulsed and PKH-26/CFSE-labeled C57BL/6.H2 g7/g7 splenocytes for 4 h. The percent-specific cytotoxicity was determined as described previously (19) .
Microarray analysis
Pancreata from mice were chopped in RPMI with 5% FCS and proteinase inhibitors, and then incubated at 37˚C in digestion buffer (50 ml RPMI, 5% FCS, 1 ml collagenase IV, 2 U/ml DNAse I, and 100 ml heparin) for 10 min. After filtering through 40-mm strainers, single-cell suspensions were pooled and AI4ab CD8 T cells were isolated by FACS sorting using anti-CD8 Ab and MimA2/H-2D b tetramer (99% purity of sorted AI4ab cells), and then immediately placed in RNAlater (Qiagen). Samples were assessed with Affymetrix Mouse Gene 1.0 ST array chips by Genomics Core Facility. Microarray data were deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE40225. The array data were imported into Expression Console v1.1 (Affymetrix), normalized after quality control, and ranked using LIMMA (R package) analysis for comparison of different groups. Three technical replicates for each group were averaged for fold change, and statistical significance was set to p , 0.05 by applying t test analysis adjusted for multiple comparisons.
Statistical analyses
Statistical significance was calculated with the unpaired t test using Prism software version 5.0b (GraphPad). A p value ,0.05 was considered statistically significant.
Results
B7x protein is not expressed on APCs or T cells in both human and mice
Because all other B7 family members are mainly expressed on APCs, we wanted to determine whether B7x protein was detected on human APCs and T cells. Using a panel of mAbs and a polyclonal Ab, we failed to detect B7x protein with flow cytometry on B cells, monocytes, and T cells from PBMC before or after stimulation: monocytes with LPS/IFN-g, B cells with LPS or PMA/ionomycin, and T cells with PHA or PMA/ionomycin (Table  I) . These stimuli were able to upregulate the expression of B7-H1 (PD-L1) or B7-2 (Supplemental Fig. 1A-C) , but not B7x (Table I) . Similarly, no B7x protein was detected on human immature DCs, immature LCs, as well as mature DCs or mature LCs stimulated with cytokine mixture, CD40L, LPS, or PMA/ionomycin (Table  I) . In contrast, B7-2 was significantly upregulated on mature DCs and LCs as the results of activation and maturation (Supplemental Fig. 1D, 1E ). As a positive control, anti-B7x Abs stained a human B7x-transfected 293 cell line (Supplemental Fig. 1F ). We recently reported that among 103 ovarian borderline tumors and carcinomas tested, all expressed B7x (20) . The tumor-infiltrating lymphocytes we observed in some of these samples, however, were B7x negative.
We recently showed that murine DCs or macrophages do not express B7x protein in vitro even after culturing in various stimulating, suppressive, and maturation conditions (4). We further isolated B and T cells, and incubated them with various stimuli: B cells with LPS, anti-IgM F(ab9) 2 , PMA/ionomycin; and T cells with Con A, plate-bound anti-CD3/CD28, PMA/ionomycin, as well as T cell subpopulations of Th1, Th2, and regulatory T cells. We did not detect B7x protein expression on these stimulated cells (Table I ). In contrast, PD-1 was induced on activated T and B cells (Supplemental Fig. 2A, 2B ). In addition, we were unable to detect B7x protein in DCs and alternatively activated macrophages from chronic Brugia malayi infection (16) or immune cells from Streptococcus pneumoniae-induced lung infection (17) . Leukocytic infiltrates in 4T1-induced lung metastatic cancer were also B7x negative (Table I ). In contrast, DCs and alternatively activated macrophages from chronic Brugia malayi infection expressed high levels of PD-L2 (Supplemental Fig. 2C ). As a positive control, a BWZ cell line overexpressing mouse B7x stained well with anti-B7x in flow cytometry (Supplemental Fig.  2D ). Collectively, these results demonstrate that, unlike any other B7 molecules, endogenous B7x protein is not expressed in the immune cells of either human or mouse.
More aggressive CD8 T cell-mediated tissue destruction in B7x-deficient mice
B7x protein is expressed in mouse pancreatic b cells (4) and human pancreas (21) . To dissect the in vivo function of B7x, we generated B7x 2/2 mice, which were born at the expected Mendelian frequency and were of normal size, maturation, and fertility. We found that B7x 2/2 mice developed more severe diabetes than wild-type control mice after the injection of activated diabetogenic BDC2.5 CD4 T cells (4) . It is unknown, however, whether tissue-expressed B7x is able to regulate CD8 T cell function in vivo. Therefore, we investigated the function of endogenous B7x in CD8 T cell-mediated tissue destruction. To address this, we took advantage of AI4ab transgenic mice that carry the rearranged TCR a-and b-chain genes (Va8Vb2) from an NOD-derived MHC class I-restricted CD8 T cell clone (11) . AI4ab CD8 T cells recognize an epitope from dystrophia myotonica kinase expressed by pancreatic b cells (12) and are capable of killing b cells and mediating overt diabetes on the C57BL/6.H2
g7/g7
background in the complete absence of CD4 T cell help (22) . We crossed B7x 2/2 mice to the C57BL/6.H2 g7/g7 background, then crossed to AI4ab mice (Fig. 1A ) and monitored diabetes development in B7x
AI4ab and AI4ab mice ( Fig. 1B-D) . We observed that the disease onset (the first day when glucose level exceeded 250 mg/dl) and the point at which 100% of mice had developed diabetes came ∼2-4 d earlier in B7x
AI4ab mice than AI4ab controls (Fig. 1B) . This trend resulted in higher average glucose levels in B7x
AI4ab mice (Fig. 1C) . Furthermore, more aggressive disease progression in B7x
AI4ab mice resulted in earlier mortality; these mice started to die roughly 16 d earlier than controls (Fig. 1D) . Considering that naive B7x 2/2 mice were healthy and that B7x deficiency in AI4ab mice resulted in more aggressive disease, these results suggest that the role of B7x in T cell regulation mainly lies in disease progression, but not in the naive steady-state.
Local expression of B7x completely abrogates CD8 T cell-mediated diabetes
In AI4ab mice, CD8 T cells are able to destroy pancreatic b cells and induce an aggressive onset of diabetes with 100% of mice exhibiting disease, and all mice ultimately die within 2 mo. B7x
AI4ab mice developed T1D earlier even than AI4ab control mice. Moreover, nearly half of B7x 2/2 AI4ab mice died by day 12
( Fig. 1D) , which made it extremely difficult to obtain enough AI4ab CD8 T cells from these mice for further functional assays. Therefore, we next examined whether B7x overexpressed in pancreatic b cells could regulate CD8 T cell-mediated tissue destruction and disease development in vivo. Rip-B7x transgenic mice overexpress B7x in pancreatic b cells under the rat insulin II promoter (4). We crossed Rip-B7x mice to the C57BL/6.H2 g7/g7
background, then crossed to AI4ab mice (Fig. 1A) and monitored diabetes in Rip-B7xAI4ab and AI4ab mice (Fig. 1B-D B7xAI4ab mice is that pathogenic CD8 T cells are unable to migrate from lymphoid tissues into the pancreas in B7x-transgenic mice. To assess this possibility, we first examined the development of insulitis in Rip-B7xAI4ab and AI4ab mice. H&E-stained pancreatic sections from around 30-d-old mice showed that RipB7xAI4ab mice, like naive C57BL/6.H2 g7/g7 mice, maintained normal islet architecture, whereas AI4ab mice lost almost all islets ( Fig. 2A, upper panels) . However, ∼23% of islets in transgenic Rip-B7xAI4ab mice had leukocytic infiltrates. We further used GAF staining to visualize b cells and found that the majority of islets in Rip-B7xAI4ab mice were intact and completely GAF + stained ( Fig. 2A, middle panels) ; however, some islets had only AI4ab, RipB7xAI4ab, and control AI4ab mice were examined for diabetes incidence (B), glucose measurements (C), and survival (D). n = 8-10 mice/group. Data are representative of three independent experiments and are presented as means 6 SEM. partial GAF + staining (Fig. 2A, lower panels) . Pancreas of AI4ab mice barely contained intact islets; therefore, no GAF + staining was detected (Fig. 2A) . Unlike the pancreas, no notable leukocyte infiltration was observed in other nonlymphoid organs such as the brain, kidney, liver, and lung in both Rip-B7xAI4ab and AI4ab mice (Fig. 2B ). These observations indicate that leukocytes are able to specifically infiltrate the pancreas of Rip-B7xAI4ab mice.
To obtain a more complete picture, we analyzed the leukocytic infiltrates from the pancreas. Single-cell suspensions prepared from the pancreas, PLN, and spleen were stained with MimA2/H2-D b tetramer and anti-CD8 Ab to detect AI4ab cells (18) , and with lineage-specific Abs to examine other immune cells. More than 95% of CD8 T cells were tetramer + in AI4ab and Rip-B7xAI4ab mice. Flow cytometry analysis showed that there were fewer AI4ab cells in the pancreas and PLN of Rip-B7xAI4ab mice than AI4ab mice (Fig. 3A) , although the difference did not reach statistical significance. In addition, there was no significant difference in the number of other immune cells, including CD4 T cells, B cells, NK cells, DCs, macrophages, and neutrophils in the pancreas, PLN, and spleen between Rip-B7xAI4ab and AI4ab mice. These data suggest that the infiltration of other immune cells in the pancreas does not significantly contribute to the phenotypic difference between Rip-B7xAI4ab and AI4ab mice.
Because ∼23% of islets in transgenic Rip-B7xAI4ab mice had leukocytic infiltrates, we asked whether the infiltrate could affect the B7x expression in islets of these mice. Immunohistochemistry analysis revealed that most islets had strong expression of B7x protein throughout (Fig. 3B, upper panels) ; however, in islets with leukocytic infiltrates, B7x + cells were confined to areas devoid of infiltrates (Fig. 3B, upper panels) , indicating a reverse correlation between B7x expression and leukocytic infiltration. As expected, pancreatic islets in AI4ab mice were barely detectable, with no obvious staining for B7x (Fig. 3B, lower panels) .
Taken together, these results suggest that AI4ab T cells in the pancreas and PLN, but not other immune cells, were associated with the disease. These observations also rule out the possibility that the absence of diabetes in B7x-transgenic mice was due to a primary defect in the ability of pathogenic CD8 T cells to infiltrate the pancreas.
B7x inhibits effector CD8 T cell-induced diabetes
To examine whether local overexpression of B7x is able to inhibit effector CD8 T cell-induced autoimmune damage, we used an adoptive transfer model of diabetes in which splenocytes from AI4ab mice induced the disease in irradiated recipients (18) . Splenocytes were isolated from 25-to 30-d-old AI4ab mice and transferred to sublethally irradiated mice at 2 3 10 7 cells/mouse (Fig. 4A ). C57BL/6.H2 g7/g7 recipients started to develop diabetes around day 10, and all progressed to the disease around day 20 ( Fig. 4B, 4C ). In contrast, no RIP-B7x recipients on C57BL/6. H2 g7/g7 background succumbed to the disease (Fig. 4B, 4C ). H&E-stained pancreatic sections from around 30 d after splenocyte transfer revealed that Rip-B7x mice had fewer leukocytic infiltrates and more normal islet architecture than C57BL/6.H2 g7/g7 mice (Fig. 4D) . Similarly, Rip-B7x recipients exhibited more GAF + staining than C57BL/6.H2 g7/g7 recipients (Fig. 4D) . Irradiation of mice usually induces profound changes including cell death and inflammation, which could complicate behavior and function of adoptively transferred T cells in vivo. Therefore, we developed a new "clean" system in which adoptively transferred CD8 T cells were capable of yielding 100% diabetes in naive, nonirradiated recipients. Splenocytes isolated from AI4ab mice were activated with MimA2 peptide and APCs in the presence of IL-2 and LPS for 5 d, which led to the expansion of effector AI4ab cells with low CD62L expression (data not shown). Adoptive transfer of 5 3 10 6 effector AI4ab cells per mouse (Fig.  5A ) rapidly induced diabetes in all C57BL/6.H2 g7/g7 recipients within 1 wk (Fig. 5B, 5C ). Again, none of the RIP-B7x recipients on C57BL/6.H2 g7/g7 background succumbed to the disease (Fig.  5B, 5C ). Thirty days after adoptive transfer of effector AI4ab cells, we further prepared single-cell suspensions from pancreas, PLN, and spleen to identify AI4ab cells using MimA2/H2-D b tetramer and an anti-CD8 Ab. Compared with control C57BL/6. H2 g7/g7 mice, Rip-B7x mice had significantly lower numbers of AI4ab cells in the pancreas (Fig. 5D) .
Taken together, the results from these two adoptive transfer models of diabetes demonstrate that B7x overexpressed in pancreatic b cells abrogates diabetes by halting effector CD8 T cellmediated tissue destruction.
Global gene expression and functional molecules in pancreatic CD8 T cells
To further understand the molecular mechanisms by which local expression of B7x abrogates effector CD8 T cell-mediated tissue destruction, we undertook a microarray analysis of AI4ab cells from the pancreas. Single-cell suspensions prepared from the pancreas from ten 25-to 30-d-old AI4ab or Rip-B7xAI4ab mice were pooled, and AI4 CD8 T cells were isolated by FACS sorting using MimA2/H2-Db tetramer and an anti-CD8 Ab. Triplicate samples from a total of 20-30 AI4ab or Rip-B7xAI4ab mice were analyzed with microarrays containing .35,000 mouse transcripts. By using high-stringency criteria for evaluation (p , 0.05, and changes of $2-fold as cutoffs), we found, unexpectedly, that only one gene transcript, Ccl3 (MIP-1a), was differentially regulated in pancreatic AI4ab CD8 T cells in Rip-B7xAI4ab mice versus control AI4ab mice (Fig. 6A, 6B) . Consistent with the microarray results, RT-PCR detected a significant amount of Ccl3 mRNA in pancreatic AI4ab CD8 T cells from Rip-B7xAI4ab mice, but not from AI4ab mice (Fig. 6B ). These data show that pancreatic effector CD8 T cells in Rip-B7xAI4ab and AI4ab mice have a similar pattern of global gene expression, and that genetic signatures of these T cells are nearly indistinguishable.
We next analyzed some key functional molecules in AI4ab T cell at the protein level. Single-cell suspensions prepared from the pancreas, PLN, and spleen were stained with MimA2/H2-D b tetramer for AI4ab cells and with Abs against functional molecules. Granzyme B (GzmB) is the most abundant component of the cytolytic granule and is a major part of the cytolytic mechanisms enabled by perforin (26) . IFN-g upregulates MHC class I expression on the b cells (27, 28) , and together with IL-1b or TNF-a, induces b cell apoptosis (29) . IFN-g is considered traditionally as a proinflammatory factor. However, studies also reveal IFN-g's anti-inflammatory effects in some autoimmune diseases (30, 31) . We examined these two cytotoxic effector molecules in g7/g7 mice and C57BL/6.H2 g7/g7 mice. Scale bars, 50 mm (left panels); 100 mm (right panels). Original magnification 320 (left panels); 310 (right panels). Data are presented as means 6 SEM and represent one of four independent experiments; n = 10 per group. AI4ab cells by intracellular staining. In spleen and PLN, the expression levels of GzmB and IFN-g in AI4ab cells from RipB7xAI4ab mice were comparable with those from AI4ab mice (Fig. 6C) . In the pancreas, GzmB levels were similar, whereas IFN-g was higher in Rip-B7xAI4ab mice than AI4ab mice but did not reach significant difference (Fig. 6C) . Because both groups of mice had low percentages of pancreatic IFN-g-producing AI4ab cells (Fig. 6C) , it was unlikely that such a low amount of IFN-g without significant difference would markedly contribute to the diabetes resistance of Rip-B7xAI4ab mice. PD-1 is a negative regulator of effector T cells (32) , and a high level of PD-1 on the surface of CD8 T cells induces cell exhaustion (33, 34) . We observed significant, yet comparable, percentages of PD-1 + AI4ab cells in both groups of mice (Fig. 6C) . We also looked at the expression of Bcl-2, a molecule involved in CD8 T cell survival and death (35) . Again, intracellular staining showed a similar level of Bcl-2 protein in AI4ab cells in both groups of mice (Fig. 6C) . These results are consistent with the microarray data and suggest that AI4ab CD8 T cells in both Rip-B7xAI4ab and AI4ab mice have a similar functional status.
Proliferation and cytotoxic function of AI4ab CD8 T cells in Rip-B7xAI4ab mice
Given that all AI4ab mice experienced development of diabetes and died, whereas Rip-B7xAI4ab mice were healthy, we next examined whether AI4ab CD8 T cells in Rip-B7xAI4ab mice were fully functional. We purified AI4ab cells from mice and examined their cytotoxic activity with MimA2 peptide-pulsed C57BL/6.H2 g7/g7 splenocytes as targets. AI4ab T cells in RipB7xAI4ab and AI4ab mice showed similar CTL activity (Fig.  7A) , suggesting that AI4ab T cells in Rip-B7xAI4ab mice maintain normal cytotoxic function. We further examined in vivo AI4ab T cell proliferation by measuring intracellular Ki-67, a cell proliferation marker. Single-cell suspensions prepared from the pancreas, PLN, and spleen were stained with MimA2/H2-D b tetramer and an anti-CD8 Ab to detect AI4ab cells, as well as an anti-Ki-67 Ab to identify proliferating cells. We found that AI4ab CD8 T cells in AI4ab mice had greater proliferation than those in RIP-B7xAI4ab mice (Fig. 7B ) but showed similar percentages of cell death in both groups of mice (Fig. 7C) . These data suggest that B7x inhibits Ag-specific CD8 T cell proliferation in vivo but does not affect the cell death of those pathogenic cells. These results also indicate that the resistance of Rip-B7xAI4ab mice to diabetes is partially due to the inhibitory effect of B7x on proliferation of pathogenic CD8 T cells.
Discussion
The expression of B7x protein has been reported inconsistently, with some studies showing B7x is induced on some immune cells (2, 3) and others reporting immune cells are B7x negative (36) . To resolve these discrepancies, we used multiple specific mAbs and polyclonal Abs to inspect B7x protein on immune cells. Although extensively examined, we were unable to detect B7x protein in human and mice immune cells under various stimulations and during infection or cancer. Therefore, we concluded that B7x protein was not expressed in immune cells. By contrast, canonical members of the B7 family such as B7-1 and B7-2 are highly expressed in APCs (37) and activated T cells (38) . B7h (ICOS ligand) is also expressed in APCs (39, 40) . Whereas PD-L2 (B7-DC) expression is mostly restricted to DCs and macrophages (41), PD-L1 (B7-H1) is widely expressed on hematopoietic cells (41, 42) and several parenchymal tissues (43, 44) . B7-H3 can be in- http://jimmunol.org/ Downloaded from duced on DCs, monocytes, and lymphocytes (45) (46) (47) . We now revealed that, unlike any other B7 family members, B7x protein was not expressed on immune cells. This finding has an important implication to understand the in vivo function of B7x.
Immune tolerance is maintained through a series of checkpoints that govern in both the thymus and the periphery (48, 49). We and others have shown that B7x protein is expressed in mice pancreatic b cells and in human pancreas (21) , and that B7x can inhibit CD4 T cell-mediated diabetes and experimental autoimmune encephalomyelitis (4) . We now further reveal that B7x expressed in pancreatic b cells has an important role in CD8 T cell-mediated pancreas-specific damage. B7x 2/2 AI4ab mice exhibited even more aggressive disease than AI4ab mice. As a consequence, B7x 2/2 AI4ab mice developed earlier lethality than AI4ab mice.
These findings unveil a crucial immunosuppressive checkpoint in which tissue-expressed B7x can inhibit self-reactive, tissuespecific CD8 T cells, and thus prevent an autoimmune disorder. Given that B7x is not expressed in immune cells, these observations also imply a B7x-dependent suppressive mechanism that operates at the effector T cell phase, not at the stage of T cell priming. Because the loss of B7x expression resulted in more severe diabetes, we also examined whether the overexpression of the molecule could prevent disease. We found that the overexpression of B7x in the pancreatic islet b cells of AI4ab mice resulted in complete abrogation of diabetes. However, the overexpression of B7x did not prevent insulitis. Rather, islet Agspecific CD8 T cells were activated in PLN and further migrated into the pancreas in B7x-transgenic mice. Indeed, in two adoptive transfer models of diabetes, the injection of activated diabetogenic CD8 T cells into B7x-transgenic animals generated insulitis but failed to induce diabetes. These results emphasize the inhibitory effect of B7x on pathogenic effector CD8 T cells. The pathogenesis of most autoimmune diseases involves multiple steps. In T1D, the insulitis phase can persist for long periods of time in humans and mice; many such prediabetic individuals never progress to overt diabetes. It is unclear which mechanisms control the conversion from the prediabetes insulitis to the diabetic state. Because overexpression of B7x in the b cells did not prevent insulitis but abrogated the progression to disease, it is conceivable that the level of B7x protein in the pancreas may be one of the factors that determine whether the insulitis phase proceeds to the diabetic state. It is known that immune cells capable of recognizing self-Ags exist in some normal individuals without causing harmful diseases. Future investigation is clearly warranted to dissect whether coinhibitory B7 molecules, such as B7x or PD-L1, prevent self-reactive immune cells in these individuals from progressing to disease by upregulating their expression in tissue cells.
Multiple mechanisms have been proposed for the peripheral tolerance of self-reactive CD8 T cells, including anergy (50), clonal deletion (50), and exhaustion (34) . In the absence of the B7-1/B7-2/CD28 pathway, Ag encounter can result in T cell anergy or deletion, whereas strong signaling of the PD-L1/PD-1 pathway can convert effector CD8 T cells into exhaustion. Importantly, CD8 T cells acquire overlapping, yet divergent molecular signatures depending on whether they are undergoing anergy, deletion, or exhaustion (35, 51) . CD8 T cells undergoing deletion exhibit GzmB and Bcl-2 downregulation (35), whereas exhausted CD8 T cells overexpress several inhibitory receptors including PD-1 and have major changes in pathways of TCR and cytokine signaling (51) . To address the molecular mechanisms of B7x-mediated inhibition of CD8 T cells, we compared the geneexpression profiles of Ag-specific pancreatic AI4ab CD8 T cells. Unexpectedly, pancreatic CD8 T cells in diabetic AI4ab mice and diabetes-free Rip-B7xAI4ab mice had a similar pattern of global gene expression. CCL3 was the only gene whose expression was statistically higher in the AI4ab T cells of RipB7xAI4ab mice. In NOD mice, the temporal expression of CCL3 in the pancreas is associated with the development of T1D (52). In humans, serum level of CCL3 is increased whereas CCL2 is decreased in the islet autoantibody-positive group relative to the autoantibody-negative group (53) . These studies demonstrate that CCL3 expression increases during the progression to T1D. However, it is unclear whether increased CCL3 is a consequence of inflammation or CCL3 itself promotes disease during T1D development. Most mature hematopoietic cells including T cells and many tissue cells including b cells produce CCL3 (54) , and whether this molecule produced by CD8 T cells has a role in the pathogenesis of diabetes is currently unknown and is open for further investigation with cell-type-specific, CCL3-deficient mouse models. Interestingly, a recent study shows that B7x-Ig protein prevents T cell proliferation and IL-2 production by inhibiting phosphorylation of ERK, JNK, p38, and AKT, but not LCK or ZAP-70 (55) , suggesting that the B7x pathway is able to rapidly interfere with the activation state of some key kinases in the CD28 pathway without markedly changing gene transcription.
Although pancreatic CD8 T cells in Rip-B7xAI4ab mice were not under immune tolerance, because these cells were able to kill target cells very well, AI4ab T cells in RIP-B7xAI4ab mice showed less proliferation than those in AI4ab mice. Moreover, Rip-B7x mice had fewer AI4 CD8 T cells in the pancreas in both spontaneous and adoptive transfer diabetes models. Therefore, what emerges is a model suggesting that B7x in the periphery prevents autoimmune diseases partially by limiting the proliferation of self-reactive, tissue-specific effector CD8 T cells in target tissues. Recent studies show that expression of B7x in islets or an insulinoma cell line prolongs allograft survival (56, 57) , and that B7x-Ig fusion protein reduces diabetes incidence in NOD mice (58) . Clearly, further studies on this new B7 pathway may lead to novel immunotherapy against autoimmune diseases. 
